Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?

Gordon A. Brown; J. Erik Busby; Christopher G. Wood; Louis L. Pisters; Colin P.N. Dinney; David A. Swanson; H. Barton Grossman; Curtis A. Pettaway; Mark F. Munsell; Ashish M. Kamat; Surena F. Matin

doi:10.1111/j.1464-410X.2006.06524.x

Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?

Gordon A. Brown, J. Erik Busby, Christopher G. Wood, Louis L. Pisters, Colin P.N. Dinney, David A. Swanson, H. Barton Grossman, Curtis A. Pettaway, Mark F. Munsell, Ashish M. Kamat, Surena F. Matin

Urology

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

OBJECTIVE: To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period. PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data. Cox's proportional hazards regression model was used to test the statistical significance of several potential prognostic factors for recurrence and survival. RESULTS: The median overall duration of follow-up was 2.5 years for 184 patients. Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02). On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS. The median recurrence-free survival duration was 2.4 years. In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence. Bladder tumours occurred in 40 (26.1%) patients with no previous cystectomy. The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS. CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed. Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol. Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.

Original language	English (US)
Pages (from-to)	1176-1180
Number of pages	5
Journal	BJU international
Volume	98
Issue number	6
DOIs	https://doi.org/10.1111/j.1464-410X.2006.06524.x
State	Published - Dec 2006

Keywords

Nephroureterectomy
Outcome
Renal pelvis
Surgery
Survival
TCC
Ureter

ASJC Scopus subject areas

Urology

Access to Document

10.1111/j.1464-410X.2006.06524.x

Cite this

Brown, G. A., Busby, J. E., Wood, C. G., Pisters, L. L., Dinney, C. P. N., Swanson, D. A., Grossman, H. B., Pettaway, C. A., Munsell, M. F., Kamat, A. M., & Matin, S. F. (2006). Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU international, 98(6), 1176-1180. https://doi.org/10.1111/j.1464-410X.2006.06524.x

@article{e6020fb0350c448b9b21c4a4d6d0d0d2,

title = "Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?",

abstract = "OBJECTIVE: To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period. PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data. Cox's proportional hazards regression model was used to test the statistical significance of several potential prognostic factors for recurrence and survival. RESULTS: The median overall duration of follow-up was 2.5 years for 184 patients. Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02). On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS. The median recurrence-free survival duration was 2.4 years. In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence. Bladder tumours occurred in 40 (26.1%) patients with no previous cystectomy. The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS. CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed. Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol. Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.",

keywords = "Nephroureterectomy, Outcome, Renal pelvis, Surgery, Survival, TCC, Ureter",

author = "Brown, {Gordon A.} and Busby, {J. Erik} and Wood, {Christopher G.} and Pisters, {Louis L.} and Dinney, {Colin P.N.} and Swanson, {David A.} and Grossman, {H. Barton} and Pettaway, {Curtis A.} and Munsell, {Mark F.} and Kamat, {Ashish M.} and Matin, {Surena F.}",

year = "2006",

month = dec,

doi = "10.1111/j.1464-410X.2006.06524.x",

language = "English (US)",

volume = "98",

pages = "1176--1180",

journal = "BJU international",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Nephroureterectomy for treating upper urinary tract transitional cell carcinoma

T2 - Time to change the treatment paradigm?

AU - Brown, Gordon A.

AU - Busby, J. Erik

AU - Wood, Christopher G.

AU - Pisters, Louis L.

AU - Dinney, Colin P.N.

AU - Swanson, David A.

AU - Grossman, H. Barton

AU - Pettaway, Curtis A.

AU - Munsell, Mark F.

AU - Kamat, Ashish M.

AU - Matin, Surena F.

PY - 2006/12

Y1 - 2006/12

N2 - OBJECTIVE: To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period. PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data. Cox's proportional hazards regression model was used to test the statistical significance of several potential prognostic factors for recurrence and survival. RESULTS: The median overall duration of follow-up was 2.5 years for 184 patients. Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02). On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS. The median recurrence-free survival duration was 2.4 years. In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence. Bladder tumours occurred in 40 (26.1%) patients with no previous cystectomy. The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS. CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed. Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol. Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.

AB - OBJECTIVE: To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period. PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data. Cox's proportional hazards regression model was used to test the statistical significance of several potential prognostic factors for recurrence and survival. RESULTS: The median overall duration of follow-up was 2.5 years for 184 patients. Significant prognosticators for disease-specific survival (DSS) by univariate analysis were tumour stage (P < 0.01), tumour grade (P < 0.01), node-positive disease (P < 0.01), multifocality (P = 0.03), previous cystectomy (P < 0.01) and synchronous bilateral UUT-TCC (P = 0.02). On multivariate analysis, only tumour stage (P = 0.03) and grade (P = 0.01) correlated with DSS. The median recurrence-free survival duration was 2.4 years. In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence. Bladder tumours occurred in 40 (26.1%) patients with no previous cystectomy. The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS. CONCLUSION: Tumour stage and grade correlated with DSS in this cohort, with no improvement in outcome over the 18-year period assessed. Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol. Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.

KW - Nephroureterectomy

KW - Outcome

KW - Renal pelvis

KW - Surgery

KW - Survival

KW - TCC

KW - Ureter

UR - http://www.scopus.com/inward/record.url?scp=33750890886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750890886&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2006.06524.x

DO - 10.1111/j.1464-410X.2006.06524.x

M3 - Article

C2 - 17125474

AN - SCOPUS:33750890886

SN - 1464-4096

VL - 98

SP - 1176

EP - 1180

JO - BJU international

JF - BJU international

IS - 6

ER -

Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this